Table 3 Patients characteristics associated with acceptance among PWH (N = 100)
Variable | Would accept injections (N = 74) | Would not accept injections (N = 26) | P |
|---|---|---|---|
Median age (IQR), years | 50 (40–56) | 52 (47–59) | 0.18 |
Sex, n (%) | 59 (80) | 17 (65) | 0.18 |
Mode of transmission, n (%) | 0.072 | ||
MSM | 41 (55) | 9 (35) | |
Heterosexual | 21 (28) | 12 (46) | |
Othera | 12 (16) | 5 (19) | |
Family life: single, n (%) | 46 (62) | 13 (50) | 0.35 |
Has children, n (%) | 29 (39) | 13 (50) | 0.36 |
Current worker, n (%) | 56 (76) | 15 (58) | 0.13 |
Travels, n (%) | 0.40 | ||
1–2/year | 34 (47) | 14 (54) | |
> 2/year | 24 (33) | 10 (38) | |
Never | 15 (21) | 2 (8) | |
Current smokers, n (%) | 15 (20) | 7 (27) | 0.58 |
Alcohol consumption: yes, n (%) | 60 (81) | 19 (73) | 0.41 |
Drugs consumption: yes n (%) | 16 (22) | 4 (15) | 0.58 |
IV drugs consumption: yes n (%) | 7 (9) | 1 (4) | 0.68 |
CDC stage, n (%) | 0.72 | ||
C | 11 (15) | 4 (15) | |
Antiviral treatment duration, n (%) | 0.24b | ||
< 1 year | 5 (7) | 0 (0) | |
1–5 year | 17 (23) | 4 (15) | |
5–10 year | 10 (14) | 6 (23) | |
> 10 year | 42 (57) | 16 (62) | |
Antiviral treatment, n (%) | 0.67 | ||
Once a day | 68 (92) | 25 (96) | |
STR, n (%) | 47 (64) | 18 (69) | 0.64 |
Median CD4 (IQR), cells/µl | 746 (521–1002) | 705 (528–805) | 0.56 |
Median CD4 nadir (IQR), cells/µl | 338 (185–446) | 292 (150–439) | 0.34 |
Hypertension, n (%) | 18 (24) | 7 (27) | 0.80 |
Diabetes, n (%) | 6 (8) | 2 (8) | > 0.99 |
Hypercholesterolemia, n (%) | 20 (27) | 13 (50) | 0.051 |
Psychiatric disorder, n (%) | 13 (18) | 2 (8) | 0.34 |
Antidepressant, n (%) | 8 (11) | 1 (4) | 0.44 |
Taking any non-HIV treatment, n (%) | 34 (46) | 11 (42) | 0.82 |
Partner aware of treatment, n (%) | 59 (80) | 17 (65) | 0.18 |
Family aware of treatment, n (%) | 37 (50) | 11 (42) | 0.65 |
Friends aware of treatment, n (%) | 39 (53) | 8 (31) | 0.069 |
Colleagues aware of treatment, n (%) | 11 (15) | 2 (8) | 0.50 |
Never experienced AEs, n (%) | 41 (55) | 20 (80) | 0.034 |
Never forgets treatment, n (%) | 48 (65) | 17 (65) | > 0.99 |